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CObjective: To assess the cost-effectiveness of lanthanum carbonate
(LC) versus sevelamer hydrochloride (SH) as a treatment for hyper-
phosphatemia in end-stage renal disease (ESRD) patients.Methods: A
Markov model was developed to estimate health outcomes; quality-
adjusted life years (QALYs) and life-years saved (LYS), as well as asso-
ciated costs. The model incorporated patient-level data from a ran-
domized head-to-head crossover study that compared the reduction of
serum phosphorus using LC and SH for 4 weeks each. The model in-
cluded patients previously treated with calcium-based binders. Both
the intent-to-treat (ITT) population and the cohort of patients who
completed treatment in both periods of the study (i.e., completer pop-
ulation) were assessed. The baseline risks of cardiovascular disease
(CVD), all-cause mortalities for CVD, and non-CVD patients were de-
rived from a large US renal database. Patient outcomes were modeled
for 10 years, and incremental cost-effectiveness ratios (ICERs) were
calculated for LC relative to SH. Deterministic and probabilistic sensi-
tivity analyses (PSA) were performed to test the robustness of the base- O
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doi:10.1016/j.jval.2011.05.043ase model. Results: For the ITT population, the ICERs of LC versus SH
ere $24,724/QALY and $15,053/LYS, respectively (in US dollars).When
he completer population was considered, the ICERs of LC versus SH
ere $15,285/QALY and $9,337/LYS (Table 2), respectively. The PSA in-
icated 61.9% and 85.8% probabilities for ITT and completer popula-
ions of LC being cost-effective at the $50,000/QALY willingness-to-
ay threshold, respectively. Conclusion: LC is a cost-effective
trategy compared with SH in the treatment of ESRD patients with
yperphosphatemia who were previously treated with calcium-
ased binders. Sensitivity analyses demonstrated the robustness of the
harmacoeconomic model.
eywords: cost-effectiveness, end-stage renal disease (ESRD), hyper-
hosphatemia, lanthanum carbonate, sevelamer hydrochloride,
arkov model.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Cardiovascular disease (CVD) is the leading cause of death in end-
stage renal disease (ESRD), accounting for 45% of all ESRD deaths [1].
CVDmortality in hemodialysis is up to 30 times greater than in gen-
eral populations and is associated with recognizable risk factors [2].
In addition to an increased risk of death, CVD is associatedwith high
rates of resource utilization. On average, dialysis patients are hospi-
talized between 1.8 and 2.4 times annually, with a mean length of
stay of 13.7 days per patient per year. Approximately 19 to 33% of
these hospitalizations are attributable to CVD [3]. The recent US Re-
nal Data System (USRDS) estimated that health-care payers spent
approximately $23 billion (in US dollars) to treat ESRD annually,
which accounted for 6.6% of the US Medicare budget in 2006 [4].
Recently, the Kidney Disease Improving Global Outcomes
KDIGO) published clinical practice guidelines on themanagement
f chronic kidney disease-mineral and bone disorder (CKD-MBD)
5]. CKD-MBD is defined as the broader clinical syndrome encom-
assing mineral, bone, and calcific cardiovascular abnormalities
* Address correspondence to: Karen L. Rascati, Eckerd/Turley Ce
College of Pharmacy, 2409 University Avenue PHR 3.209, Austin, T
E-mail: krascati@mail.utexas.edu.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.that develop as complications of CKD [5]. Disturbed mineral and
bone metabolism is common in CKD patients, especially abnor-
malities in serum calcium, phosphorous, and parathyroid hor-
mone levels. It is an important cause of morbidity and decreased
health-related quality of life in CKD patients [6]. Importantly,
these disorders in mineral and bone metabolism have been asso-
ciated with increased cardiovascular calcification, morbidity, and
mortality [7] and result in a high burden of economic costs (studies
ublished in 2007 to 2008 of treatment costs for CKD-MBD ranged
rom £25,033 [US$41,722] to CAN$157,500 [US$143,182] per QALY
ained) [8]. Specifically, high phosphorous levels have been asso-
iated with a greater risk (vs. lower phosphorus levels) for all-
ause and cardiovascular mortality, and for hospitalizations due
o both cardiovascular events and fractures [9–12]. Consequently,
hosphate control has become an important therapeutic target in
KD, primarily to reduce the risk of vascular calcification and car-
iovascular mortality [13].
Treatment guidelines issued by the US National Kidney Foun-
ation’s Kidney Disease Outcomes Quality Initiative (K/DOQI) rec-
nial Professor of Pharmacy Administration, University of Texas
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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between 3.5 and 5.5 mg/dl for patients with CKD (stage 5) [14].
About 90% of dialysis patients continue to require oral phosphate
binders [15] due to limited effectiveness of dietary phosphate re-
triction [16,17] and insufficiency of hemodialysis to maintain
phosphate levels within recommended targets [13].
Themost commonly used phosphate binders are calcium salts.
Calcium-based binders (calcium carbonate and calcium acetate)
have been the standard of care in phosphate-binding therapy for
almost 20 years and are relatively inexpensive [18]. Calcium salts,
however, have been associatedwith an increased risk of hypercal-
cemia and vascular calcification, especially with long-term or
high-dose use [19,20]. In addition, the K/DOQI panel recommends
that the daily calcium intake from phosphate binders should not
exceed 1500mg/day, which could limit the use of calcium-based
binders [14]. Thus, there is significant interest in the optimal use of
noncalcium binders to achieve and maintain K/DOQI targets [21].
Lanthanum carbonate (LC), sevelamer hydrochloride (SH), and
sevelamer carbonate are noncalcium, nonaluminum binders
available in the United States [15]. (Sevelamer carbonate was ap-
proved by the FDA in 2007; no head-to-head trial with sevelamer
carbonate was available at the time of this study.) In clinical prac-
tice, noncalcium binders are substituted for existing calcium-
based binders to maintain K/DOQI target and to avoid the adverse
events of calcium-based binders.
To date, the cost-effectiveness of SH versus calcium salts [22–
25] and LC versus calcium salts [26] has been studied; but to our
nowledge, a cost-effectiveness comparison between LC and SH
as not been published. Therefore, the purpose of this study is to
ssess the cost-effectiveness of LC comparedwith SH for the treat-
ent of hyperphosphatemia in patients with ESRD who were pre-
iously treated with a calcium-based binder from the US payer
erspective.
Methods
Decision-analytic model and assumptions
A Markov model was built in Excel 2007 (Microsoft Corp., Red-
mond, WA) to compare the two noncalcium binders (LC vs. SH) in
patients with ESRD and hyperphosphatemia who were previously
treated with calcium-based binder therapy. Transitions between
Fig. 1 – Markov model diagram of lanthanum carbonate versfour relevant clinical states were considered: alive without CVD,alive with CVD, non-CVD patients’ all-cause death, and CVD patients’
all-cause death (Fig. 1). Similar to previous cost-effectiveness stud-
ies of phosphate binders and medications for the prevention of
CVD based on clinical opinion [24,27,28], yearly transitions were
used for the probability of developing CVD event. In the model, all
patients started in alive without CVD. From this health state, serum
phosphorus level-specific probabilities were used to estimate
transitions to CVD, non-CVD patients’ all-cause death, CVD patients’
all-cause death, or remain alive without CVD. Once in the CVD state,
atients could not go back to alive without CVD state; they could
ither remain in this state or progress to CVD patients’ all-cause
eath. Transition probabilities of CVD and survival were based on
he data provided by the USRDS (see below). It was assumed that
atients continued to receive medications (either LC or SH) until
eath, and despite regular dialysis and dietary advice, hyperphos-
hatemia is an ongoing problem for most patients with ESRD. The
ase-case model was analyzed for 10 years, with5 years consid-
red in the sensitivity analysis. Both costs and outcomes were
iscounted at 5% in the base-case analysis and the discount rate
as varied from 0% to 10% in the sensitivity analysis [29].
Efficacy data
Patient-level data on the efficacy of LC and SH in ESRD with hy-
perphosphatemia were taken from Sprague et al. [30], a random-
izedhead-to-head crossover study,which compared the reduction
of serum phosphorus with LC and SH. Patients were included in
that study if their serumphosphorus and calciumvalues exceeded
6.0mg/dl and8.4mg/dl, respectively, after a 2- to 3-weekwash-
out period. The patients were randomized (1:1) to receive either LC
(2250mg/day for the firstweek and then increased to 3000mg/day)
or SH (4800mg/day for the first week and then increased to 6400
mg/day) after the initial washout period. After 4 weeks of treat-
ment, patients underwent a second washout period (2 weeks) and
switched to the alternative binder for 4 weeks. To be reflective of
common clinical practice with regard to the place in therapy for
treatment with LC and SH, patients were included in the decision
model if they had previously used a calcium-based binder (cal-
cium, calcium acetate, or calcium carbonate) on entering the
study.
The intent-to-treat (ITT) population was used in the base-case
model. This population included all trial patients who previously
used a calcium-based binder and received at least one dose of
evelamer hydrochloride. CVD, cardiovascular disease.us seither LC (n  148) or SH (n  140), and had at least one valid
1004 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 0 2 – 1 0 0 9postdose serumphosphorusmeasurement using the last observa-
tion carried forward. A secondary analysis of the completer pop-
ulation was conducted, which included all patients who previ-
ously used a calcium-based binder and completed the full 4-week
treatment with both drugs and had a valid serum phosphorus
measurement at the end of each treatment period (n  106).
For a Markov model, a simulated cohort is created, and base-
line cohort characteristics of simulated patients included in our
model were based on themeans and standard deviations of serum
phosphorus levels at week 4 (end of period 1) and at week 10 (end
of period 2) from the study by Sprague et al. [30].
Transition probabilities
Probability of CVD
Transition probabilities for moving from alive without CVD to the
alive with CVD state were based on data from the USRDS 2002 an-
nual report [31]. In the cardiovascular epidemiological study, CVD
rates and survival were analyzed over a 5-year period for 295,913
Medicare-eligible incident dialysis patients who had been on dial-
ysis for at least 1 year in 1995 to 1999. The CVD probability was
calculated using the weighted average of the mutually exclusive
five most common CVDs in ESRD patients from the USRDS: 1)
acute myocardial infarction; 2) congestive heart failure; 3) cardiac
arrest; 4) peripheral vascular disease; and 5) cerebrovascular acci-
dent. The probabilities of concurrent CVDs were not included. Be-
cause we were interested in the primary CVD event associated
with high phosphorus levels, we did not simulate concurrent
CVDs after a primary event. The CVD probability was extrapolated
for 15 years based on data from the USRDS report, fitted with a
Weibull model (S[t] exp {-t},  0.1711,  0.8964) (Fig. 2). The
Weibull model is appropriate for survival modeling when events
occur early in the follow-up time period [32]. The annual CVD
probability for patients with higher serum phosphorus was esti-
mated by applying the relative risk (RR) estimates corresponding
to their serum phosphorus level. The estimated RRs of CVD were
derived from a study by Block et al. [9], which determined associ-
ations among disorders of mineral metabolism, mortality, and
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Fig. 2 – Cardiovascular disease probability. Cardiovascular
event-free curve for US Renal Data System (USRDS)
incident dialysis patients and adjusted curve for patients
without an increased risk from elevated phosphorus
levels.morbidity in 40,538 hemodialysis patients in the United States.
Similar methods were used to estimate the probabilities of death
for CVD and non-CVD patients.
Probability of CVD patients’ all-cause death.
The annual probability of CVD survival (i.e., 1-p [Death]) in ESRD
patients was estimated from the same population that provided
the estimated probability of transitioning to CVD. As previously
described, CVD survival was extrapolated from the USRDS report
data and fitted using a Weibull model (S[t]  exp {-t},   0.7544,
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Fig. 3 – Probability of cardiovascular disease patients’
mortality. Cardiovascular event survival curve for US Renal
Data System (USRDS) incident dialysis patients and
adjusted curve for patients without an increased risk from
elevated phosphorus levels.
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1005V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 0 2 – 1 0 0 9  0.7014). This was adjusted by serum phosphorus levels to es-
timate the probabilities of CVD patients’ all-cause mortality (Fig.
3). To account for the increased risk of death with higher serum
phosphorus levels, the baseline CVD patient’s all-cause mortality
was multiplied by phosphorus-specific RRs of CVD mortality [11].
CVDmortality risk categories by phosphorus levelswere identified
for 25,588 dialysis patients in the dialysis outcomes and practice
patterns study by Tentori et al. [11].
Probability of non-CVD patients’ all-cause death.
Baseline estimates for the annual survival for ESRD patients were
derived from the USRDS 2009 annual report for 10 years. After
using aWeibullmodel (S[t] exp {t},  0.2188,  0.8934) [26],
nnual survival associated with serum phosphorus levels was ob-
ained by multiplying the baseline probability by the estimated
Rs provided by Tentori et al. [11] (Fig. 4).
Costs
All costs used in the model were reported in 2009 US dollars and
are summarized in Table 1. Drug costs were estimated using the
Table 1 – Model inputs.
Parameter Base-case
assumption
PE
Mean (SD) of SP
ITT population LC: 5.665 (1.919)
LC (n  148), SH (n  140) SH: 5.925 (1.663)
Completer population LC: 5.539 (1.655)
LC (n  106), SH (n  106) SH: 6.023 (1.544)
RR
RR of CVD associated with SP range 5.0 mg/dl: 1.00
5.0–6.0 mg/dl: 1.10
6.0–7.0 mg/dl: 1.15
7.0–8.0 mg/dl: 1.29
8.0–9.0 mg/dl: 1.28
9.0 mg/dl: 1.38
RR of CVD patients’ mortality associated
with SP range
3.5 mg/dl: 1.08
3.6–5.0 mg/dl: 1.00
5.1–6.0 mg/dl: 1.25
6.1–7.0 mg/dl: 1.61
7.0 mg/dl: 1.81
RR of non-CVD patients’ mortality
associated with SP range
3.5 mg/dl: 1.06
3.6–5.0 mg/dl: 1.00
5.1–6.0 mg/dl: 1.02
6.1–7.0 mg/dl: 1.18
7.0 mg/dl: 1.43
Cost
Drug cost LC: $7,599/year
SH: $7,475/year
CVD cost
Alive $26,393 (first year)
$5,279 (subsequent yea
Died $20,967
Utility
Utility of ESRD 0.674
Utility of CVD 0.736 (first year)
0.773 (subsequent year
Costs are given in US dollars.
95% CI, 95% confidence interval; CVD, cardiovascular disease; ESRD, e
not applicable; PE, point estimate; RR, relative risk; SD, standard deviationUS average wholesale price (AWP) [33]. The average doses of LC
and SH applied in the model were taken from the administered
doses reported in Sprague et al. [30]. The cost of LC at a dose of 3000
mg/day (3 tablets at 1000mg each)was $20.82/day and that of SH at
a dose of 6400 mg/day (8 tablets at 800 mg each) was $20.48/day.
Medication adherence was assumed to be 82% in the first year of
treatment, which was extrapolated from the clinical trial [30], and
ropped to 70% after the first year based on a cohort study of
hosphate binder adherence [34].
The estimated costs of treating CVD were derived from multi-
le sources. A weighted average of five CVD costs was calculated:
cute myocardial infarction [35], congestive heart failure [23], car-
iac arrest [36], peripheral vascular disease [23], and cerebrovas-
ular accident [23]. The proportional distributions of CVD inci-
ents among ESRD patients observed in the USRDS study were
sed to weight the frequency of each CVD event which was
atchedwith the corresponding cost [31]. CVDmaintenance costs
ere assumed to be 20% of first-year event costs [23]. In addition,
VD mortality costs were estimated based on the costs for pa-
ients that died, categorized by the place of death (e.g., hospital,
Probabilistic sensitivity
assumptions
Reference or data
source
Plausible ranges
considered
Distribution
Patient level data from
clinical trial [30]
NA NA
PE  15% Log normal Block et al. [9]
95% CI Log normal Tentori et al. [11]
95% CI Log normal Tentori et al. [11]
PE  10% Gamma Average dose from
clinical trial [30] and
price per unit [33]
PE  10% Gamma
PE  20% Gamma [23,35,36]
PE  20% Gamma [23,35–37]
95% CI Beta [38]
PE  20% Beta [28,36,39–41]
age renal disease; ITT, intent-to treat; LC, lanthanum carbonate; NA,r)
)
nd-st
; SH, sevelamer hydrochloride; SP, serum phosphorus.
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1006 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 0 2 – 1 0 0 9home) reported by the USRDS [37]. The cost of renal dialysis was
ot included in the model because the modeling study focused on
he incremental, or additional, costs of using either LC or SH and
ccurrence of CVD.
Quality of life
The quality-of-life estimate at baseline for all patientswas derived
from a study reporting utility values for patients on dialysis [38].
To capture the decrease in quality of life associated with the oc-
currence of CVD events, utilities were multiplied by 0.7357 (a
weighted average utility of five CVD events [28,36,39–41]) for the
first year and increased by 5% for subsequent years [28]. The stud-
ies of time-tradeoff utilities of CVD found that amean utility score
improved over time [42,43].
Sensitivity analyses
Ranges for RRs, costs of CVD and LC, utilities, discount rates, and
number of cycles were included in one-way deterministic sensi-
tivity analyses. A probabilistic sensitivity analysis (PSA; second-
order Monte Carlo simulation) involving 1000 random samples
was also conducted. The effect of varying individual values for
RRs, costs, and utilities was calculated using plausible ranges of
values from the literature and/or 95% confidence intervals (CIs).
When 95% CIs were not available, ranges up to 20% in each direc-
tion were used. Log-normal distributions for RRs, beta distribu-
tions for utilities, and gamma distributions for costs were used
[44,45]. Table 1 summarizes the characteristics of variables used in
the PSA.
Results
Base-case analyses
The estimated costs and benefits of LC compared with SH for the
ITT and the completer populations are provided in Table 2. In the
ITT population analysis, the 10-year discounted total cost for pa-
tients treated with LC was $48,575, whereas the discounted total
cost for the SH group was $47,959 (incremental cost $616). Esti-
mated discountedQALYs gainedwere 3.078 for LC and 3.053 for SH
(incremental QALY gained 0.025). With these estimates, the ICER
of LC compared with SH was $24,724 per QALY gained. When life
expectancy alone was considered, the ICER was $15,053 per LYS
for LC versus SH treatment.
In the secondary analysis, when the outcomes of patients who
completed 4 weeks of treatment with both drugs (completer pop-
ulation, N 106) were used, the discounted total cost over 10 years
or patients treated with LC was $48,816, compared to $47,881 for
H, producing an incremental cost of $936. For patients treated
ith LC, the discounted incremental QALYs gain was 0.061 QALYs
Table 2 – Base-case model results for ESRD patients treated
completer populations over a 10-year period (LC versus SH
Group Total cost Incremental
cost
In
ITT population LC: $48,575
SH: $47,959
$616
Completer population LC: $48,816
SH: $47,881
$936
Costs are given in US dollars.
ESRD, end-stage renal disease; ICER, incremental cost-effectiveness r
QALY, quality-adjusted life years; SH, sevelamer hydrochloride.nd LYS was 0.100. The estimated ICERs of LC compared with SH
mproved to $15,285 per QALY gained and $9,337 per LYS.
Deterministic sensitivity analyses
Sensitivity analyses performed on key input parameters indicated
that the cost-effectiveness results were robust within the range of
plausible assumptions for ITT and completer populations (Table
3). Using these ranges for varying input estimates, the RRs of CVD,
mortality, CVD-specificmortality, the discount rate, and the num-
ber of model cycles had little to moderate impact on ICERs, be-
cause the ICERs changed less than 20% for each of these vari-
ables. Results of the base-case model were most sensitive to
variations in phosphate binder drug costs. When the price of LC
was increased by 10%, the ICER increased to $111,898 per QALY
gained and $51,094 per QALY gained for ITT and completer popu-
lations, respectively. A 10% decrease of LC cost indicated domi-
nance of LC for ITT and completer groups.
Probabilistic sensitivity analyses
Figure 5 presents the scatter-plot diagrams with a maximumwill-
ingness-to-pay (WTP) of $50,000/QALY, which is the joint distribu-
tion of the mean incremental costs and mean incremental effects
for a cohort of 1000 patients. All of the estimates fell in quadrants
I and II of the cost-effectiveness plane. Thus, results of the PSA,
which are depicted in Figure 5, suggest that LC was either more
costly and more effective, or less costly and more effective than
SH. Themean values for each groupwere used to generate accept-
ability curves over a range of WTP values. The cost-effectiveness
acceptability curve illustrates a 61.9% probability of LC being cost-
effective at the $50,000 WTP threshold (Fig. 6). In addition, the
figure indicates that the likelihood of LC being cost-effective for
the completer population increased to 85.8% at the $50,000 WTP
level.
Discussion
Several previous economic evaluations have reported the benefits
of LC or SH over traditional calcium-based binders, but a cost-
effectiveness study had yet to be conducted comparing two non-
calcium binders, LC and SH [22–26,46]. To our knowledge, this is
the first analysis to examine the cost-effectiveness of using LC
compared with SH in the treatment of hyperphosphatemia in
ESRD patients previously treated with calcium-based binders. In
the base-case analysis, when efficacy data was incorporated from
the ITT population using the last observation carried forward
method, patients assigned to LC had slightly higher total costs
($616) but greater QALYs (0.025 years) and greater survival (0.041
years), yielding ICERs of $24,724 per QALY gained and $15,053 per
LYS.
viously with a calcium-based binder for ITT and
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Incremental
LYS
ICERs
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25 0.041 $24,724 $15,053
61 0.100 $15,285 $9,337
ITT, intent-to-treat; LC, lanthanum carbonate; LYS, life-years saved;pre
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treatment with both binders (i.e., the completer population). This
populationmay bemore pertinent to clinical practice and economic
considerationsbecause thesepatients receivedphosphatebinders at
the maintenance dose for the intended duration. When data from
the completer population was used in the model, the estimated IC-
ERs of LC versus SH improved to $15,285/QALY and $9,337/LYS. This
resultwas largely drivenby the statistically significant greater reduc-
tionof serumphosphoruswithLCcomparedwithSHamongpatients
who completed both treatments in the clinical trial.
Our model incorporated data from large epidemiological stud-
ies to calculate the relationship between high serum phosphorus
levels and increased RRs of mortality, CVD incidence, and CVD
mortality as described by Block et al. [9] and Tentori et al. [11]. The
previous cost-effectiveness studies comparing SH versus calcium-
based binders used clinical trial results [22,24] or surrogate end-
point-electron beam tomography calcification scores to predict
the CVD risk in ESRD patients [23]. Our study uniquely incorpo-
Table 3 – One-way deterministic sensitivity analysis.
Variables considered within
sensitivity analysis
ITT popu
ICERs per QALY
gained
Base-case scenario $24,724
RR
RR of non-CVD patients’ mortality associated with SP range (varied w
Lower bound of 95% CI $24,787
Upper bound of 95% CI $24,488
RR of CVD associated with SP range (95% CI not provided; therefore v
RR reduced by 15% $25,826
RR increased by 15% $23,937
RR of CVD patients’ mortality associated with SP range (varied within
Lower bound of 95% CI $25,357
Upper bound of 95% CI $24,142
Cost
Drug price (LC)
Cost reduced by 10% Dominant
Cost increased by 10% $111,898
CVD
Cost reduced by 20% $24,969
Cost increased by 20% $24,480
Compliance
Assuming that drug compliance
is 0.5 for subsequent year
$18,485
Utility
ESRD (varied within 95% CI)
0.58 $28,710
0.78 $21,349
CVD (95% CI not provided; therefore varied from 20% to 20%)
0.589 (first year),
0.618 (subsequent year)
$26,687
0.883 (first year),
0.927 (subsequent year)
$23,031
Discount rate for costs and effects
0% $23,753
10% $25,922
Cycle
5 years $27,982
15 years $24,316
Costs are given in US dollars.
CVD, cardiovascular disease; ESRD, end-stage renal disease; ICER, in
years saved; QALY, quality-adjusted life years; RR, relative risk; SH, sates the RRs of CVD and mortality associated with phosphoruslevels using CVD incidence and survival based on US nationwide
epidemiological studies. Given the difficulty of conducting long-
term studies in this population, the best evidence on CVD rates
and CVD survival to date has been provided by the USRDS. Impor-
tantly, our analysis was robust to reasonable variation of RRs for
CVD and mortality, indicated by the sensitivity analyses.
The cost of CVD mortality was included in this analysis as the
USRDS 2005 annual report showed a spike in per person per month
costs of CKD patients before death (i.e., five times and four times
higher than 12 month and 6 month prior costs, respectively) [37].
These costs were incorporated in the economic model because of
their important role in the total cost for this population. Costs for
concurrent CVDs, hypercalcemia, and dialysis were not included in
our analysis, whichmight underestimate the total costs. These costs,
however,areexpectedtobesimilar forbothtreatments (LCandSH)and
therefore we have assumed that the incremental costs would poten-
tially beminimally affected [24–26]. Similarly, side effects of treatment
were not included in the model because there were no significant dif-
n Completer population
ICERs per LYS ICERs per QALY
gained
ICERs per
LYS
$15,053 $15,285 $9,337
95% CI)
$15,084 $15,154 $9,233
$14,931 $15,430 $9,452
from 15% to 15%)
$15,857 $15,437 $9,514
$14,463 $15,242 $9,236
CI)
$15,562 $15,285 $9,467
$14,585 $15,345 $9,273
Dominant Dominant Dominant
$68,127 $51,094 $31,211
$15,202 $15,367 $9,387
$14,904 $15,203 $9,287
$11,255 $11,279 $6,890
$15,053 $17,749 $9,337
$15,053 $13,198 $9,337
$15,053 $16,446 $9,337
$15,053 $14,277 $9,337
$14,389 $15,517 $9,433
$15,866 $15,136 $9,293
$17,596 $12,405 $7,812
$14,693 $16,282 $9,873
ental cost-effectiveness ratios; LC, lanthanum carbonate; LYS, life-
mer hydrochloride; SP, serum phosphorus.latio
ithin
aried
95%
cremferences between treatments reported in the clinical trial [30].
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model was robust to reasonable ranges for most variables, includ-
ing variation in the RRs, CVD costs, and utilities. Our base-case
model, however, was sensitive to phosphate binder drug costs.
Thus, drug costs varied by 10% in the PSA, in addition to plausi-
ble ranges for RRs, CVD costs, and utilities. As a result, the proba-
bility that the use of LC would be cost-effective if a decisionmaker
was willing to pay $50,000 per QALY gained was 61.9% for the ITT
population and 85.8% for the completer population. This analysis
suggests that the collective variability did not threaten the validity
of the analysis results for the cost-effectiveness of LC versus SH.
Similar to other cost model analyses, limitations of this analy-
sis stem from the use of a mix of data sources and the multiple
assumptions. The efficacy data from the randomized clinical trial
(RCT) was based on posterior serum phosphorus levels from a
relatively short duration of follow-up. Estimated outcomes for 10
years were modeled based on this short-term data. On the other
hand, this clinical trial was the only available head-to-head anal-
ysis comparing the reduction of serum phosphorus in ESRD pa-
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Fig. 5 – Cost-effectiveness plane of lanthanum carbonate ver
populations with a maximum wiliness-to-pay level of $50,0
adjusted life years.
Fig. 6 – Cost-effectiveness acceptability curves of
lanthanum carbonate for ITT and completer populations.oITT, intent-to-treat.tients treatedwith LC versus SH. Furthermore, the crossover study
design reduced the influence of confounding covariates because
each patient served as his or her own control.
Another limitation was the assumption that the serum phos-
phorus level for each patient did not change during the simula-
tion. Little long-term serum phosphorus level data for SH was
found. However, studies on LC support our assumptions. Finn et
al. [47] reported that themean serum phosphorus level of 5.7 2.0
mg/dl at week 4 was maintained as 5.7  1.4 mg/dl at week 52 in
patients receiving hemodialysis from the long-term safety study
of LC. The longest study published on the continued administra-
tion of phosphate-binder therapy in dialysis patients byHutchison
et al. [48], found that themean serumphosphorus level in patients
receiving LC was maintained for up to 6 years.
An additional limitation of this study is that the estimate of the
probability of death from non-CVD causes for ESRD patients with
CVD fromtheUSRDS2002annual reportwasnot available [31]. In the
odel, the proportion of CVD patients who died from CVD causes
ersus non-CVD causes was not separated. We used the estimated
R of CVD mortality to calculate the risk of CVD patients’ all-cause
ortality because thisRR is theonly availablemortality risk estimate
or CVD patients associated with their serum phosphorus level [11].
herefore, these estimates used for RR and cost of CVD mortality
ay be an overestimate. However, using these estimates, we found
hat 50%of thismodeled studypopulationdiedduring 5years,which
s comparable to the 49% to 51% of the ESRD population who died
romCVD during 5 years based on the USRDS 2005 data [37]. In addi-
ion, one-way sensitivity analyses were robust to the variation in RR
f CVDmortality and CVD cost.
In conclusion, as demonstrated in this economic evaluation, LC
rovides therapeutic benefits for ESRD patients previously treated
ith a calcium-based binder who need to switch to a non-calcium
inder. The greater reduction in phosphorus with LC versus SH
esulted in significant risk reductions in CVD incidence and all-
ause mortalities for CVD and non-CVD patients, with slightly
igher total costs from the US payer perspective. Although there
re uncertainties inherent in using modeling to estimate long-
erm outcomes based on short-term clinical trial data, the results
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sevelamer hydrochloride for ITT and completer
S dollars) per QALYs. ITT, intent-to-treat; QALY, quality-Q
Q
sus
00 (Uf our study suggest that LC is a cost-effective treatment for ESRD
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1009V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 0 2 – 1 0 0 9patients with hyperphosphatemia previously treated with cal-
cium binders when compared with SH. This model, based on
head-to-head comparisons, can be used to inform decision-mak-
ers where cost-effectiveness is part of decision-making process.
Source of financial support: Shire Pharmaceuticals provided a
research grant to the University of Texas (Karen Rascati, Haesuk
Park) for this project. Michael S. Keith, Paul Hodgkins, andMichael
Smyth are employees of Shire. David Goldsmith and Ron Akehurst
were consultants for Shire.
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